Executive readout · one minute
Call research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
ERNA
$4.17
+3.61%
ERNA
· Ernexa Therapeutics Inc.
$4.17
+0.15 (+3.61%)
At close · Sep 11
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$6.80M
Shares
1.63M
All earnings calls
Earnings call · FY2020 Q2
Ernexa Therapeutics Inc. (ERNA) Q2 2020 Earnings Call
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Revenue
$754,000
-85.6% YoY
Diluted EPS
-$900.00
Net income
-$2.03M
Research materials
Open the source you need; every reader stays inside this workspace.
SEC filing · Item 2.02
8-K earnings release
Filed Aug 7, 2020 · complete as-filed document
SEC periodic report
10-Q report
Filed Aug 7, 2020 · complete as-filed document